Education
About Us
Working with TipRanks
Follow Us
Oxford BioDynamics PLC (GB:OBD)
LSE:OBD
OBD Stock Chart & Stats
0.24 p
0.04 p(3.63%)
At close: 4:00 PM EST
0.24 p
0.04 p(3.63%)
Day’s Range― - ―
52-Week Range0.20 p - 0.78 p
Previous CloseN/A
Volume22.58K
Average Volume (3M)21.87M
Market Cap
£10.73M
Enterprise Value9.05M
Total Cash (Recent Filing)£1.39M
Total Debt (Recent Filing)£5.11M
Price to Earnings (P/E)―
Beta-0.79
Next Earnings
Jun 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding4,290,911,000
10 Day Avg. Volume50,883,470
30 Day Avg. Volume21,870,725
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.90
Price to Sales (P/S)6.02
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)£2.32M
Bulls Say, Bears Say
Bulls Say
Proprietary EpiSwitch PlatformOwnership of the EpiSwitch epigenetic biomarker platform provides a durable technology moat for diagnostic and companion diagnostic development. Persistent IP and platform-driven assays support repeatable revenue from service, licensing, and test commercialization across oncology and autoimmune indications.
Diversified Revenue Model (services, Licensing, Collaborations)A multi-channel commercial model (contract research, licensing, royalties and academic/industry collaborations) spreads revenue exposure and builds long-term partner ties. This mix supports recurring project work and licensing income as the platform is adopted across drug development and diagnostics ecosystems.
Reported High Revenue GrowthMaterial top-line expansion indicates rising demand for the company’s services and platform. Sustained revenue growth provides scale benefits, enhances partner credibility, and gives management optionality to invest in commercialization and R&D that can compound platform value over the medium term.
Bears Say
High Financial LeverageA debt-to-equity ratio of 4.58 signals heavy reliance on external financing, constraining strategic flexibility. Elevated leverage increases interest and refinancing risk, making it harder to fund R&D or commercial rollouts organically and raising vulnerability to adverse funding conditions.
Persistent Negative ProfitabilityNegative gross, EBIT and net margins show the company struggles to convert revenue into profit sustainably. Ongoing operating losses erode equity, limit internal reinvestment capacity, and mean long-term viability depends on either durable margin improvement or continued external funding.
Weak And Deteriorating Cash GenerationA -33.93% decline in free cash flow growth and negative operating cashflow-to-income indicate cash burn and weak conversion of earnings into liquidity. This heightens dependency on debt/equity raises, amplifying dilution or solvency risk and constraining long-term investment capacity.
Oxford BioDynamics News
OBD FAQ
What was Oxford BioDynamics PLC’s price range in the past 12 months?
Oxford BioDynamics PLC lowest share price was 0.20 p and its highest was 0.78 p in the past 12 months.
What is Oxford BioDynamics PLC’s market cap?
Oxford BioDynamics PLC’s market cap is £10.73M.
When is Oxford BioDynamics PLC’s upcoming earnings report date?
Oxford BioDynamics PLC’s upcoming earnings report date is Jun 02, 2026 which is in 85 days.
How were Oxford BioDynamics PLC’s earnings last quarter?
Currently, no data Available
Is Oxford BioDynamics PLC overvalued?
According to Wall Street analysts Oxford BioDynamics PLC’s price is currently Overvalued.
Does Oxford BioDynamics PLC pay dividends?
Oxford BioDynamics PLC does not currently pay dividends.
What is Oxford BioDynamics PLC’s EPS estimate?
Oxford BioDynamics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oxford BioDynamics PLC have?
Oxford BioDynamics PLC has 4,290,911,000 shares outstanding.
What happened to Oxford BioDynamics PLC’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Oxford BioDynamics PLC?
Currently, no hedge funds are holding shares in GB:OBD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oxford BioDynamics PLC
Oxford BioDynamics Plc, a biotechnology company, discovers and develops biomarkers for use in the pharmaceutical and biotechnology industry primarily in the United States and internationally. The company provides EpiSwitch, a proprietary technology platform for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures for use in medical testing kits, disease prediction, diagnosis, and treatment. Its products include EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic test for predicting response to checkpoint inhibitor immunotherapy; EpiSwitch CST (Covid Severity Test), an advanced blood test for the prediction of COVID-19 severity in adults; and EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery. Oxford BioDynamics Plc was incorporated in 2007 and is headquartered in Oxford, the United Kingdom.
Technical Analysis
IXICO plc
―
SkinBioTherapeutics
―
Fusion Antibodies Plc
―
Genflow Biosciences Plc
―
Aptamer Group Plc
―
Options Prices
Currently, No data available
---